Search

Your search keyword '"Braunwald, Eugene"' showing total 4,871 results
Start Over Author "Braunwald, Eugene"

Refine your results

more »

more »

more »

more »

more »
4,871 results on '"Braunwald, Eugene"'

51. Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction:Insights from the PARADISE-MI Trial

Author

Petrie, Mark C., Rouleau, Jean L., Claggett, Brian, Jering, Karola, Van Der Meer, Peter, Køber, Lars, Miao, Zi Michael, Lewis, Eldrin, Granger, Christopher, De Pasqulae, Carmine G., Mann, Douglas, Steg, Philippe Gabriel, Maggioni, Aldo, Amir, Offer, Lefkowitz, Marty, Braunwald, Eugene, Solomon, Scott D., McMurray, John J.V., Pfeffer, Marc A., Petrie, Mark C., Rouleau, Jean L., Claggett, Brian, Jering, Karola, Van Der Meer, Peter, Køber, Lars, Miao, Zi Michael, Lewis, Eldrin, Granger, Christopher, De Pasqulae, Carmine G., Mann, Douglas, Steg, Philippe Gabriel, Maggioni, Aldo, Amir, Offer, Lefkowitz, Marty, Braunwald, Eugene, Solomon, Scott D., McMurray, John J.V., and Pfeffer, Marc A.

Published
2024

52. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.

Author

Bergmark, Brian A., Park, Jeong-Gun, Hamershock, Rose A., Melloni, Giorgio E. M., De Caterina, Raffaele, Antman, Elliott M., Ruff, Christian T., Rutman, Howard, Mercuri, Michele F., Lanz, Hans-Joachim, Braunwald, Eugene, and Giugliano, Robert P.

Abstract

BACKGROUND: Cardiovascular trials often use a composite end point and a time-to-first event model. We sought to compare edoxaban versus warfarin using the win ratio, which offers data complementary to time-to-first event analysis, emphasizing the most severe clinical events. METHODS: ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a double-blind, randomized trial in which patients with atrial fibrillation were assigned 1:1:1 to a higher dose edoxaban regimen (60/30 mg daily), a lower dose edoxaban regimen (30/15 mg daily), or warfarin. In an exploratory analysis, we analyzed the trial outcomes using an unmatched win ratio approach. The win ratio for each edoxaban regimen was the total number of edoxaban wins divided by the number of warfarin wins for the following ranked clinical outcomes: 1: death; 2: hemorrhagic stroke; 3: ischemic stroke/systemic embolic event/epidural or subdural bleeding; 4: noncerebral International Society on Thrombosis and Haemostasis major bleeding; and 5: cardiovascular hospitalization. RESULTS: 21 105 patients were randomized to higher dose edoxaban regimen (N=7035), lower dose edoxaban regimen (N=7034), or warfarin (N=7046), yielding >49 million pairs for each treatment comparison. The median age was 72 years, 38% were women, and 59% had prior vitamin K antagonist use. The win ratio was 1.11 (95% CI, 1.05-1.18) for higher dose edoxaban regimen versus warfarin and 1.11 (95% CI, 1.05-1.18) for lower dose edoxaban regimen versus warfarin. The favorable impacts of edoxaban on death (34% of wins) and cardiovascular hospitalization (41% of wins) were the major contributors to the win ratio. Results consistently favored edoxaban in subgroups based on creatine clearance and dose reduction at baseline, with heightened benefit among those without prior vitamin K antagonist use. CONCLUSIONS: In a win ratio analysis of the ENGAGE AF-TIMI 48 trial, both dose regimens of edoxaban were superior to warfarin for the net clinical outcome incorporating ischemic and bleeding events. As the win ratio emphasizes the most severe clinical events, this analysis supports the superiority of edoxaban over warfarin in patients with atrial fibrillation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

55. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

Author

Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., and Braunwald, Eugene

Published
2020
Full Text
View/download PDF

59. Causes of late mortality with dual antiplatelet therapy after coronary stents

Author

Mauri, Laura, Elmariah, Sammy, Yeh, Robert W, Cutlip, Donald E, Steg, P Gabriel, Windecker, Stephan, Wiviott, Stephen D, Cohen, David J, Massaro, Joseph M, D'Agostino, Ralph B, Braunwald, Eugene, and Kereiakes, Dean J

Subjects
Cancer, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Heart Disease - Coronary Heart Disease, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aspirin, Cause of Death, Drug Therapy, Combination, Drug-Eluting Stents, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Neoplasms, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Pyridines, Treatment Outcome, Dual antiplatelet therapy, Mortality, Thienopyridine, DAPT Study Investigators, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsIn the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.Methods and resultsPatients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).ConclusionBleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer.Trial registrationclinicaltrials.gov Identifier: NCT00977938.

Published
2016

60. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

Author

Patel, Siddharth M., primary, Morrow, David A., additional, Bellavia, Andrea, additional, Berg, David D., additional, Bhatt, Deepak L., additional, Jarolim, Petr, additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Raz, Itamar, additional, Steg, P. Gabriel, additional, Wilding, John P. H., additional, Sabatine, Marc S., additional, Wiviott, Stephen D., additional, Braunwald, Eugene, additional, Scirica, Benjamin M., additional, and Bohula, Erin A., additional

Published
2023
Full Text
View/download PDF

61. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

Author

Schou, Morten, primary, Claggett, Brian, additional, Miao, Zi Michael, additional, Fernandez, Alberto, additional, Filippatos, Gerasimos, additional, Granger, Christopher, additional, Jering, Karola, additional, Maggioni, Aldo P., additional, McCausland, Finnian, additional, Villota, Julio Nuñez, additional, Rouleau, Jean‐Lucien, additional, Mody, Freny Vaghaiwalla, additional, van der Meer, Peter, additional, Vinereanu, Dragos, additional, McGrath, Martina, additional, Zhou, Yinong, additional, Mann, Douglas L., additional, Solomon, Scott D., additional, Steg, Philippe Gabriel, additional, Braunwald, Eugene, additional, McMurray, John J.V., additional, Pfeffer, Marc A., additional, and Køber, Lars, additional

Published
2023
Full Text
View/download PDF

62. Cardiovascular effects of climate change.

Author

Braunwald, Eugene

Subjects
GREENHOUSE gases, MEDICAL personnel, YOUNG adults, CLIMATE change & health, BLOOD flow measurement, HEAT stroke
Abstract

Climate change poses significant challenges to human health, including cardiovascular effects. The World Health Organization (WHO) recognizes climate change as a fundamental threat to human health, with 3.6 billion people already living in high-risk areas. Climate change is caused by human activity, particularly the combustion of fossil fuels, which leads to the emission of greenhouse gases. Excessive heat, a signature component of climate change, has profound effects on the cardiovascular system, increasing the risk of heat-related illnesses and cardiovascular events. To mitigate climate change, a transition from fossil fuels to renewable energy is necessary, requiring collaboration between policymakers and the healthcare system. Cardiologists and their societies have an important role to play in raising awareness, developing guidelines, and advocating for action on climate change. [Extracted from the article]

Published
2024
Full Text
View/download PDF

67. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Author

Pfeffer, Marc A., Claggett, Brian, Lewis, Eldrin F., Granger, Christopher B., Køber, Lars, Maggioni, Aldo P., Mann, Douglas L., McMurray, John J.V., Rouleau, Jean-Lucien, Solomon, Scott D., Steg, Philippe Gabriel, Berwanger, Otavio, Cikes, Maja, De Pasquale, Carmine G., Fernandez, Alberto, Filippatos, Gerasimos, Jering, Karola, Landmesser, Ulf, Menon, Venugopal, Merkely, Béla, Petrie, Mark C., Petrov, Ivo, Schou, Morten, Senni, Michele, Sim, David, van der Meer, Peter, Lefkowitz, Martin, Zhou, Yinong, Wang, Yi, and Braunwald, Eugene

Published
2022
Full Text
View/download PDF

69. Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy

Author

Desai, Milind Y. and Braunwald, Eugene

Abstract

A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these molecules.

Published
2024
Full Text
View/download PDF

74. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

Author

Patel, Siddharth M., Morrow, David A., Bellavia, Andrea, Berg, David D., Bhatt, Deepak L., Jarolim, Petr, Leiter, Lawrence A., McGuire, Darren K., Raz, Itamar, Steg, P. Gabriel, Wilding, John P.H., Sabatine, Marc S., Wiviott, Stephen D., Braunwald, Eugene, Scirica, Benjamin M., and Bohula, Erin A.

Subjects
DAPAGLIFLOZIN, BRAIN natriuretic factor, NATRIURETIC peptides, BODY mass index, HEART failure, HEART metabolism disorders, RISK assessment
Abstract

Aim: N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT‐proBNP with respect to heart failure risk remains incompletely defined. Methods and results: Data were pooled across three randomized clinical trials enrolling predominantly patients who were overweight or obese with established cardiometabolic disease: SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT‐proBNP. The effect of dapagliflozin versus placebo was assessed for a treatment interaction across BMI categories in patients with or without an elevated baseline NT‐proBNP (≥125 pg/ml). Among 24 455 patients, the median NT‐proBNP was 96 (interquartile range [IQR]: 43–225) pg/ml and the median BMI was 33 (IQR 29–37) kg/m2, with 68% of patients having a BMI ≥30 kg/m2. There was a significant inverse association between NT‐proBNP and BMI which persisted after adjustment for all clinical variables (p < 0.001). Within any range of NT‐proBNP, those at higher BMI had higher risk of HHF at 2 years (comparing BMI <30 vs. ≥40 kg/m2 for NT‐proBNP ranges of <125, 125–<450 and ≥450 pg/ml: 0.0% vs. 0.6%, 1.3% vs. 4.0%, and 8.1% vs. 13.8%, respectively), which persisted after multivariable adjustment (adjusted hazard ratio [HRadj] 7.47, 95% confidence interval [CI] 3.16–17.66, HRadj 3.22 [95% CI 2.13–4.86], and HRadj 1.87 [95% CI 1.35–2.60], respectively). In DECLARE‐TIMI 58, dapagliflozin versus placebo consistently reduced HHF across BMI categories in those with an elevated NT‐proBNP (p‐trend for HR across BMI = 0.60), with a pattern of greater absolute risk reduction (ARR) at higher BMI (ARR for BMI <30 to ≥40 kg/m2: 2.2% to 4.7%; p‐trend = 0.059). Conclusions: The risk of HHF varies across BMI categories for any given range of circulating NT‐proBNP. These findings showcase the importance of considering BMI when applying NT‐proBNP for heart failure risk stratification, particularly for patients with low‐level elevations in NT‐proBNP (125–<450 pg/ml) where there appears to be a clinically meaningful absolute and relative risk gradient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

78. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 inhibition in Patients with Type 2 Diabetes

Author

Moura, Filipe A., primary, Berg, David D., primary, Bellavia, Andrea, primary, Dwyer, Jamie P., primary, Mosenzon, Ofri, primary, A. Scirica, Benjamin, primary, Wiviott, Stephen D., primary, Bhatt, Deepak L., primary, Raz, Itamar, primary, Feinberg, Mark W., primary, Braunwald, Eugene, primary, Morrow, David A., primary, and Sabatine, Marc S., primary

Published
2023
Full Text
View/download PDF

79. Foreword

Author

Braunwald, Eugene, primary, Zipes, Douglas P., additional, Libby, Peter, additional, Bonow, Robert O., additional, and Tomaselli, Gordon F., additional

Published
2020
Full Text
View/download PDF

83. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention

Author

Tricoci, Pierluigi, Newby, L. Kristin, Clare, Robert M., Leonardi, Sergio, Gibson, C. Michael, Giugliano, Robert P., Armstrong, Paul W., Van de Werf, Frans, Montalescot, Gilles, Moliterno, David J., Held, Claes, Aylward, Philip E., Wallentin, Lars, Harrington, Robert A., Braunwald, Eugene, Mahaffey, Kenneth W., and White, Harvey D.

Published
2018
Full Text
View/download PDF

85. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease

Author

Bansilal, Sameer, Bonaca, Marc P., Cornel, Jan H., Storey, Robert F., Bhatt, Deepak L., Steg, Ph. Gabriel, Im, Kyungah, Murphy, Sabina A., Angiolillo, Dominick J., Kiss, Robert G., Parkhomenko, Alexander N., Lopez-Sendon, Jose, Isaza, Daniel, Goudev, Assen, Kontny, Frederic, Held, Peter, Jensen, Eva C., Braunwald, Eugene, Sabatine, Marc S., and Oude Ophuis, A.J.

Published
2018
Full Text
View/download PDF

87. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Marston, Nicholas A., Patel, Parth N., Kamanu, Frederick K., Nordio, Francesco, Melloni, Giorgio M., Roselli, Carolina, Gurmu, Yared, Weng, Lu-Chen, Bonaca, Marc P., Giugliano, Robert P., Scirica, Benjamin M., O’Donoghue, Michelle L., Cannon, Christopher P., Anderson, Christopher D., Bhatt, Deepak L., Gabriel Steg, Philippe, Cohen, Marc, Storey, Robert F., Sever, Peter, Keech, Anthony C., Raz, Itamar, Mosenzon, Ofri, Antman, Elliott M., Braunwald, Eugene, Ellinor, Patrick T., Lubitz, Steven A., Sabatine, Marc S., and Ruff, Christian T.

Published
2021
Full Text
View/download PDF

88. Autophagy in Chronically Ischemic Myocardium

Author

Yan, Lin, Vatner, Dorothy E., Kim, Song-Jung, Ge, Hui, Masurekar, Malthi, Massover, William H., Yang, Guiping, Matsui, Yutaka, Sadoshima, Junichi, Vatner, Stephen F., and Braunwald, Eugene

Published
2005

95. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

Author

Vaduganathan, Muthiah, primary, Mentz, Robert J, additional, Claggett, Brian L, additional, Miao, Zi Michael, additional, Kulac, Ian J, additional, Ward, Jonathan H, additional, Hernandez, Adrian F, additional, Morrow, David A, additional, Starling, Randall C, additional, Velazquez, Eric J, additional, Williamson, Kristin M, additional, Desai, Akshay S, additional, Zieroth, Shelley, additional, Lefkowitz, Martin, additional, McMurray, John J V, additional, Braunwald, Eugene, additional, and Solomon, Scott D, additional

Published
2023
Full Text
View/download PDF

96. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Author

Jering, Karola S., primary, Claggett, Brian L., additional, Pfeffer, Marc A., additional, Granger, Christopher B., additional, Køber, Lars, additional, Lewis, Eldrin F., additional, Maggioni, Aldo P., additional, Mann, Douglas L., additional, McMurray, John J.V., additional, Prescott, Margaret F., additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Steg, Phillippe Gabriel, additional, von Lewinski, Dirk, additional, and Braunwald, Eugene, additional

Published
2023
Full Text
View/download PDF

98. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Patel, Parth N, Marston, Nicholas A, Kamanu, Frederick K, Weng, Lu Chen, Bonaca, Marc P, Giugliano, Robert P, Scirica, Benjamin M, OʼDonoghue, Michelle L, Cannon, Christopher P, ANDERSON, Christopher D, Bhatt, Deepak L, Steg, Philippe G, Cohen, Marc, Storey, Robert F, Sever, Peter S, Keech, Anthony C, RAZ, Itamar, Mosenzon, ofri, Braunwald, Eugene, Ellinor, Patrick T, Lubitz, Steven A, Sabatine, Marc S, and Ruff, Christian T

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results